Maithili Life Sciences Showcases Innovation at Pharmaconex 2024
Maithili Life Sciences recently marked a successful participation at Pharmaconex 2024 in Cairo, Egypt, from September 8th to 10th. As one of the MENA region’s most prestigious pharmaceutical events, Pharmaconex was an excellent platform to connect with key industry stakeholders and highlight our comprehensive range of high-quality Active Pharmaceutical Ingredients (APIs) and intermediates.
Strengthening Our Presence in the MENA Market
Our involvement in Pharmaconex reflects our strategic focus on expanding in the Middle East and North Africa (MENA) region. Egypt, with its growing pharmaceutical sector, is a pivotal market for Maithili Life Sciences. The event allowed us to showcase our capabilities, explore local partnerships, and further establish our brand as a trusted supplier of pharmaceutical ingredients in the region.
Key Highlights from the Event
- Engaging with Industry Leaders:
We had the opportunity to engage in insightful discussions with local and international pharmaceutical companies, distributors, and regulatory bodies. These discussions centered on quality standards, innovative solutions, and the future of healthcare in the MENA region. - Showcasing Our Diverse Product Range:
Our comprehensive API portfolio garnered significant interest. We exhibited a wide range of APIs and intermediates across therapeutic areas such as cardiovascular, CNS, anti-infective, oncology, and more. These offerings are aligned with the evolving needs of the Egyptian pharmaceutical industry. - Commitment to Compliance and Quality:
One of the core pillars of our discussions at Pharmaconex was our unwavering commitment to international quality standards like USFDA, EU-GMP, and WHO-GMP. Our products adhere to stringent regulatory requirements, making us a reliable partner for pharmaceutical companies seeking top-tier ingredients.
Expanding Our API Portfolio in Egypt
Pharmaconex also served as a platform to introduce our latest API and intermediates, which cater to a variety of therapeutic segments. Our portfolio includes:
- Azilsartan Medoxomil Potassium Salt: An angiotensin II receptor antagonist used to treat high blood pressure.
- Benazepril HCl: An ACE inhibitor for treating hypertension.
- Irbesartan: Used to treat high blood pressure and diabetic nephropathy.
- Nebivolol HCl: A beta-blocker that treats high blood pressure.
- Telmisartan: An angiotensin receptor blocker (ARB) for managing hypertension.
- Brivaracetam: Used as an anticonvulsant for epilepsy.
- Modafinil: Promotes wakefulness in conditions like narcolepsy.
- Rasagiline Mesylate: Used in the treatment of Parkinson’s disease.
- Trazodone: An antidepressant used for major depressive disorder.
- Ornidazole: An antibiotic used to treat infections caused by anaerobic bacteria and protozoa.
- Favipiravir: An antiviral used to treat influenza and COVID-19.
- Voriconazole: An antifungal medication for serious fungal infections.
- Etoricoxib: A COX-2 inhibitor for osteoarthritis and rheumatoid arthritis.
- Zaltoprofen: A non-steroidal anti-inflammatory drug (NSAID).
- Cabergoline Intermediates: Used in the treatment of hyperprolactinemia and pituitary tumors.
- Dabigatran Etexilate Mesylate: An anticoagulant used to prevent strokes and blood clots.
- Darolutamide Intermediates: Used in the treatment of non-metastatic castration-resistant prostate cancer.
- Minoxidil: Primarily used for its ability to promote hair growth.
- Dapoxetine HCl: Used for treating premature ejaculation.
- Solifenacin Succinate: Used to treat overactive bladder.
- Sumatriptan Succinate: For the treatment of migraine headaches.
- Tadalafil: Used to treat erectile dysfunction and benign prostatic hyperplasia.
- Tamsulosin: Treats benign prostatic hyperplasia.
- Ticagrelor: An antiplatelet medication to reduce cardiovascular events.
- Torsemide: A diuretic for treating edema and hypertension.
- Sildenafil: Treats erectile dysfunction and pulmonary arterial hypertension.
- Vardenafil: Used to treat erectile dysfunction.
Our ongoing focus is on expanding this product line to meet the growing demands of the Egyptian market, especially in areas such as oncology, cardiovascular diseases, and anti-infective solutions.
Forging New Partnerships in Egypt
Pharmaconex provided an ideal venue to connect with local pharmaceutical companies and distributors, forming new partnerships that will facilitate our growth in the region. We discussed customized solutions for clients, ensuring that our APIs and intermediates not only meet local regulatory needs but also exceed industry expectations in terms of quality and innovation.
Contact Us
For more information about Maithili Life Sciences and our extensive range of APIs and intermediates, please contact us at [email protected] or visit our website www.maithililifesciences.com.
Maithili Life Sciences: Empowering the Future of Healthcare in Egypt and Beyond
